Glenmark Pharmaceuticals Limited
GLENMARK
주식 순위
#2741
Glenmark Pharmaceuticals Limited, including its associated entities, is a... Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
주가
$24.39
마지막 동기화: 2026-10-19
시가총액
$6.88B
변동 (1일)
-1.20%
변동 (1년)
15.69%
국가
IN
거래 Glenmark Pharmaceuticals Limited (GLENMARK)
카테고리
Healthcare
Glenmark Pharmaceuticals Limited (GLENMARK)의 발행 주식 수
June 2026 기준 발행 주식 수: 282.20M
Glenmark Pharmaceuticals Limited의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 282.20M입니다. March 2024 말 기준 회사는 282.17M주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Glenmark Pharmaceuticals Limited (GLENMARK)의 발행 주식 수 기록 (2004 ~ 2026)
매년 말 기준 발행 주식 수
| 연도 | 발행 주식 수 | 변화 |
|---|---|---|
| 2026 (TTM) | 282.20M | 0.00% |
| 2025 | 282.19M | 0.01% |
| 2024 | 282.17M | 0.00% |
| 2023 | 282.17M | -0.01% |
| 2022 | 282.20M | 0.01% |
| 2021 | 282.17M | 0.00% |
| 2020 | 282.17M | 0.00% |
| 2019 | 282.18M | 0.00% |
| 2018 | 282.17M | -0.04% |
| 2017 | 282.27M | 0.51% |
| 2016 | 280.84M | 3.52% |
| 2015 | 271.30M | 0.06% |
| 2014 | 271.14M | 0.10% |
| 2013 | 270.88M | 0.18% |
| 2012 | 270.38M | 0.13% |
| 2011 | 270.04M | 3.56% |
| 2010 | 260.76M | 4.29% |
| 2009 | 250.03M | 2.21% |
| 2008 | 244.62M | 2.73% |
| 2007 | 238.12M | 0.33% |
| 2006 | 237.33M | 0.07% |
| 2005 | 237.16M | 3.69% |
| 2004 | 228.71M | 0.00% |
유사 기업 또는 경쟁사의 발행 주식 수
| 회사 | 발행 주식 수 | 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 750.23% |
IN
|
